Triptorelin
An FDA-approved GnRH agonist for advanced prostate cancer and central precocious puberty, used outside the US for endometriosis, IVF, and breast cancer ovarian suppression, and discussed in bodybuilding circles as an unproven post-cycle 'restart'.
What is Triptorelin?
Triptorelin is a synthetic decapeptide GnRH superagonist (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2) that, in animal studies, showed 13-fold higher LH-releasing and 21-fold higher FSH-releasing activity than native GnRH. A D-tryptophan substitution at position 6 confers enhanced receptor affinity and resistance to enzymatic degradation. Like other GnRH agonists, continuous administration causes an initial gonadotropin flare followed by profound pituitary desensitization, leading to medical castration levels of sex hormones. Triptorelin was first FDA-approved in 2000 (Trelstar) for advanced prostate cancer, and in 2017 (Triptodur) for central precocious puberty. It is also widely used internationally for endometriosis and as part of IVF protocols.
What Triptorelin Is Investigated For
Triptorelin is investigated and FDA-approved for advanced prostate cancer (Trelstar) and central precocious puberty (Triptodur), and is widely used internationally for endometriosis, uterine fibroids, IVF protocols, and ovarian suppression in premenopausal breast cancer. The strongest evidence is across the full GnRH agonist class indications, with triptorelin-specific support from the GETUG 14 radiotherapy trial, the Trelstar and Triptodur registration studies, the TEXT and SOFT breast cancer trials, and Phase 3 endometriosis and precocious puberty trials (the PRIORITI post-prostatectomy trial, by contrast, did not reach statistical significance). It lowers testosterone about as well as leuprolide and goserelin, though a 2018 systematic review concluded there are too few head-to-head trials to call the agents formally equivalent; in practice, selection is driven by formulation availability and depot interval. The honest caveats are class-level rather than triptorelin-specific: the initial testosterone or estrogen flare during the first 1–2 weeks requires anti-androgen pre-loading in high-tumor-burden prostate cancer, extended ADT causes bone mineral density loss and carries increased cardiovascular and metabolic risk, and recovery of gonadal function after discontinuation is gradual and incomplete in some older men. The bodybuilding-forum claim that a single 100 mcg dose 'resets' the HPG axis after anabolic steroid use rests on one published case report, has no controlled trial support, can backfire badly if a long-acting depot product is used instead, and is prohibited for male athletes under WADA class S2.
History & Discovery
Triptorelin emerged from the European GnRH analog development effort in the late 1970s and early 1980s, parallel to (and sometimes pre-dating) the leuprolide work in the United States. The molecule — a decapeptide with D-tryptophan at position 6 — was developed by the Tulane group of Andrew Schally, who co-received the 1977 Nobel Prize: a 1976 paper from Coy, Schally, and colleagues reported that D-Trp6-LH-RH was 13 times more active than native LH-RH in rats. Commercial development was led by the Swiss company Debiopharm. The D-Trp6 substitution conferred substantially enhanced receptor binding affinity and metabolic stability over native GnRH, making it among the most potent GnRH superagonists in the class. Triptorelin was first registered in France in 1986 — which Debiopharm describes as the world's first registered sustained-release GnRH agonist formulation — and is now marketed through licensees including Ipsen and Ferring in more than 80 countries. In the United States, triptorelin pamoate (Trelstar) was developed by Debiopharm, first licensed in the US to Pharmacia (whose rights passed to Pfizer in 2003) and now distributed by Verity Pharmaceuticals, and received FDA approval in June 2000 for advanced prostate cancer — entering a market dominated by leuprolide. Triptodur (22.5 mg 6-month depot) was FDA-approved in June 2017 for central precocious puberty in pediatric patients age 2 and older, dosed as a single intramuscular injection once every 24 weeks. Globally, triptorelin has broader approval than in the US — particularly for endometriosis (Decapeptyl is widely used across Europe, Asia, and Latin America), uterine fibroids, breast cancer in premenopausal women (where ovarian suppression complements adjuvant endocrine therapy in selected patients), in-vitro fertilization protocols, and male contraception research. Recent practice treats triptorelin, leuprolide, and goserelin as broadly interchangeable options within the GnRH agonist class (a 2018 systematic review found similar castration effects but too few head-to-head trials to prove equivalence), with selection driven by formulation availability, depot interval preference, payer access, and clinician familiarity rather than meaningful efficacy differences.
How It Works
Triptorelin mimics the brain's natural GnRH hormone but is far more potent and long-lasting. When given continuously (via depot injection), it overwhelms the pituitary's GnRH receptors, causing them to shut down. This stops LH and FSH production, which in turn halts testosterone and estrogen production — effectively a reversible chemical castration useful for hormone-sensitive cancers and conditions.
Triptorelin (D-Trp6-GnRH) is a decapeptide superagonist with a D-tryptophan substitution at position 6 that increases binding affinity and metabolic stability. In animal studies it had 13-fold higher LH-releasing and 21-fold higher FSH-releasing activity than native GnRH, and in cultured rat pituitary cells it was 100-fold more active at releasing LH. Acute administration triggers robust LH/FSH release via Gq/11-coupled GnRH receptor (GnRHR) signaling. Sustained exposure (depot formulations) causes receptor internalization, uncoupling from phospholipase C signaling, and transcriptional downregulation of GnRHR expression. The net result is castrate-level testosterone (<50 ng/dL) within 3-4 weeks. Depot formulations use biodegradable polymer microsphere technology (PLGA) for sustained release over 1, 3, or 6 months. Triptorelin pamoate and triptorelin acetate salt forms are used depending on formulation and release profile.
Evidence Snapshot
Human Clinical Evidence
Extensive. FDA-approved for advanced prostate cancer (2000) and central precocious puberty (2017). Widely used internationally for endometriosis and IVF. Triptorelin-specific evidence includes the GETUG 14 Phase 3 randomized trial, a 284-man head-to-head randomized trial versus leuprolide, the TEXT and SOFT breast cancer trials, and large real-world cohorts such as the observational TALISMAN study; the PRIORITI Phase 4 randomized trial did not reach statistical significance.
Animal / Preclinical
Comprehensive. GnRH receptor desensitization and HPG axis suppression thoroughly characterized in rodent and primate models.
Mechanistic Rationale
Very strong. GnRH receptor pharmacology, pituitary desensitization kinetics, and HPG axis regulation are well-established. D-amino acid substitution at position 6 and its effect on receptor binding and metabolic stability are well-characterized.
Research Gaps & Open Questions
What the current literature has not yet settled about Triptorelin:
- 01Head-to-head triptorelin vs. leuprolide comparative outcomes — most class-level data treat the agents as interchangeable, but adequately powered head-to-head trials are limited; subtle differences in testosterone suppression onset, cardiovascular safety, and quality-of-life endpoints might exist.
- 02GnRH agonist vs. antagonist class selection in patients with cardiovascular comorbidity — the PRONOUNCE trial (degarelix vs. leuprolide) was stopped early after enrolling 545 of 900 planned men and found no difference in major cardiovascular events (5.5% vs 4.1%), and no dedicated triptorelin trial exists; optimal selection in high cardiovascular-risk patients remains debated.
- 03Single-dose 'restart' use after anabolic-androgenic steroids — the published evidence is one 2010 case report. The only registered single-dose study in healthy men (two volunteers, 0.1 mg) measured urine drug levels for doping control and has posted no hormone results, and no trial has compared triptorelin with standard approaches for steroid-induced hypogonadism.
- 04IVF outcomes by agonist choice — a 52-woman randomized study found lower implantation and pregnancy rates with depot triptorelin than with depot leuprolide in the long protocol; whether this reflects a real difference needs confirmation in larger trials.
- 05Fertility protection during chemotherapy — triptorelin cut chemotherapy-induced early menopause from 25.9% to 8.9% in the PROMISE-GIM6 trial, but long-term follow-up found no statistically significant difference in pregnancies, so whether it meaningfully preserves fertility is unresolved.
- 06Optimal dose and duration of ovarian suppression in premenopausal breast cancer — international guidelines recommend triptorelin or goserelin in selected high-risk premenopausal women receiving tamoxifen or aromatase inhibitors, but optimal duration and patient-selection refinement is ongoing.
- 07Pediatric long-term outcomes after central precocious puberty treatment — long-term effects on adult height, bone density, fertility, and metabolic health following pediatric GnRH agonist treatment courses are being characterized in registry data.
- 08Combination with novel anti-androgens in biochemical recurrence — EMBARK established enzalutamide combinations; further sequencing and combination questions with apalutamide, darolutamide, and novel agents are evolving.
Forms & Administration
In the US, all triptorelin products are intramuscular injections: Trelstar 3.75 mg every 4 weeks, 11.25 mg every 12 weeks, or 22.5 mg every 24 weeks for prostate cancer. Triptodur: 22.5mg 6-month depot for central precocious puberty. Outside the US, Decapeptyl and related brands come as 1-, 3-, and 6-month depots; some 3-month versions can be given under the skin (in a 126-man study, subcutaneous triptorelin pamoate 11.25 mg kept 96.6% of men castrated at 26 weeks), and a short-acting injection is used in IVF. All depot formulations use biodegradable PLGA microgranules or microspheres for sustained release. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Advanced prostate cancer: 3.75 mg monthly IM depot (Trelstar Depot), 11.25 mg 3-month depot (Trelstar LA), or 22.5 mg 6-month depot (Trelstar 6-Month). Decapeptyl SR (international) 3.75 mg monthly or 11.25 mg 3-month depot. Central precocious puberty: 22.5 mg every 24 weeks (Triptodur), or 11.25 mg every 12 weeks in international markets; a 2026 UK multicentre study of 164 children found 24-weekly and 12-weekly Decapeptyl SR gave equivalent hormonal suppression and pubertal control. Endometriosis (international, off-label US): 3.75 mg monthly depot for up to 6 months. IVF protocol use: 0.1 mg daily SC (long protocol) or 3.75 mg single-dose depot (depot suppression protocol); as an ovulation trigger in GnRH antagonist cycles, a single short-acting dose of 0.2 to 0.4 mg has been studied, with no difference in mature eggs across that range.
Frequency
Depot injection at the labeled interval (monthly, 3-month, or 6-month). Daily SC formulation exists for IVF but is uncommon outside that context.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Prostate cancer ADT is typically chronic indefinite for metastatic disease, time-limited (6 months to several years) when used as adjuvant to definitive radiation in localized high-risk disease, or intermittent in selected biochemical-recurrence patients. Endometriosis treatment is typically up to 6 months without add-back hormonal therapy, with longer durations possible when add-back is used. Central precocious puberty treatment continues until appropriate physiologic age for puberty.
Protocol Notes
Triptorelin's clinical management mirrors leuprolide closely. The initial testosterone or estrogen flare during the first 1–2 weeks requires anti-androgen pre-loading in advanced prostate cancer (bicalutamide, flutamide) to mitigate flare-related symptoms in patients with significant tumor burden, particularly bone metastases or impending spinal cord compression. In endometriosis and fibroid use, the flare can transiently worsen pain symptoms; patients should be counseled. Bone mineral density loss with extended ADT is the principal long-term complication and merits proactive management identical to leuprolide-treated patients. Cardiovascular comparisons between antagonists and agonists have used leuprolide, not triptorelin. The PRONOUNCE trial (degarelix vs. leuprolide) was stopped early and found no difference in major cardiovascular events at 1 year (5.5% vs 4.1%), while a 2023 meta-analysis of 14 studies found fewer cardiovascular events with antagonists, mainly in men with existing cardiovascular disease. Triptorelin-specific data are lacking, so the class-level signal is extrapolated. Hot flashes, fatigue, mood changes, and decreased libido are predictable and should be discussed in advance. Triptorelin in the off-label 'PCT' (post-cycle therapy) context popularized in bodybuilding culture — typically a single 100 mcg subcutaneous dose to trigger an LH/FSH surge after anabolic-androgenic steroid use — has no controlled clinical trial support and no defined safety profile; the published evidence is one 2010 case report. The clearest documented risk is using a long-acting depot product, which suppresses testosterone for weeks rather than restoring it. This use is not endorsed and is mentioned here only because patients may ask about it. US triptorelin products (Trelstar, Triptodur) are intramuscular injections that the labels say must be given by, or under the supervision of, a healthcare provider, and the Trelstar suspension must be injected within 2 minutes of mixing. Some ex-US 3-month formulations are also used subcutaneously. Leuprolide's Eligard, by comparison, is a subcutaneous injection of a polymer matrix. In IVF, triptorelin has two distinct roles: pituitary suppression before stimulation (long protocol, daily or depot dosing) and, in GnRH antagonist cycles, a single-dose trigger that provokes the woman's own LH surge to mature the eggs. In the first report, LH peaked about 4 hours after 0.2 mg; in a 165-donor dose-finding trial the surge was brief, and one donor still developed severe early ovarian hyperstimulation syndrome.
Triptorelin is FDA-approved for advanced prostate cancer (Trelstar) and central precocious puberty (Triptodur). Endometriosis use is FDA off-label (though widely approved internationally as Decapeptyl). Off-label PCT use following anabolic steroid use has no clinical evidence base and is not supported. Triptorelin should be prescribed by a clinician familiar with the relevant indication.
Timeline of Effects
Onset
After first depot injection, an initial LH/FSH and consequent testosterone or estrogen 'flare' occurs over the first 7–14 days. Pituitary desensitization develops over the next 2–4 weeks. Castrate-level testosterone is achieved in most prostate cancer patients by week 3–4. PSA and other clinical response markers begin declining by 4–8 weeks. In the central precocious puberty indication, suppression of stimulated LH and slowing of bone-age progression is observed over the first months.
Peak Effect
Maximal hormonal suppression is sustained throughout the depot interval with appropriate redosing. PSA decline in advanced prostate cancer typically continues through months 1–6 to a nadir level that is prognostic. BMD loss progresses with continued ADT. In central precocious puberty, sustained pituitary suppression maintains pre-pubertal hormone levels for the duration of treatment.
After Discontinuation
Recovery of pituitary function and gonadal hormone production after discontinuation is gradual — in a US series of 76 men (median 15 months of ADT with leuprolide, goserelin, triptorelin, or degarelix), the median time for testosterone to recover to at least 240 ng/dL was 19 months, and older age and longer treatment predicted slower recovery. The HERO trial found much faster recovery after the oral antagonist relugolix than after the agonist leuprolide (54% vs 3.2% above 280 ng/dL at 90 days); triptorelin was not part of HERO. In premenopausal women, menstrual cycles typically resume within 1–6 months after discontinuation. In central precocious puberty, the Triptodur label expects the effect on pituitary and gonadal function to disappear within six to twelve months after stopping; in long-term follow-up of 50 girls treated with depot triptorelin, all had menarche or resumed periods (mean age 12.3 years).
Common Questions
What is a triptorelin 'trigger shot' in IVF?
In IVF cycles that use a GnRH antagonist to prevent early ovulation, a single small injection of short-acting triptorelin — 0.2 to 0.3 mg in most published studies — can replace or add to hCG to trigger final egg maturation, by provoking the pituitary's own LH surge. In the first report, LH peaked about 4 hours after a 0.2 mg dose and none of eight women at high risk of ovarian hyperstimulation syndrome developed it. In a dose-finding trial in 165 egg donors, 0.2, 0.3, and 0.4 mg gave the same number of mature eggs; the surge was brief, and one donor still developed severe early hyperstimulation. This is a different use from the long protocol, where daily or depot triptorelin suppresses the pituitary before stimulation.
Is triptorelin used in breast cancer?
Yes, outside its US labels. In the TEXT and SOFT trials, premenopausal women with hormone receptor-positive early breast cancer had ovarian function suppressed with triptorelin, surgery, or radiation, plus exemestane or tamoxifen for 5 years; exemestane with ovarian suppression raised 5-year disease-free survival from 87.3% to 91.1%, and the 15-year final results published in 2026 found the overall survival benefit concentrated in higher-risk women. Separately, in the PROMISE-GIM6 trial, triptorelin given during chemotherapy cut early menopause from 25.9% to 8.9%, although pregnancy rates did not differ significantly on long-term follow-up.
Is triptorelin banned in sport?
For men, yes, at all times. The WADA Prohibited List (2026, unchanged in 2027) places GnRH and its agonist analogues, naming triptorelin, under S2.2.1, 'Testosterone-stimulating peptides in males'. That class is prohibited in and out of competition and consists of non-Specified substances. A man with a genuine medical need, such as prostate cancer, can apply for a Therapeutic Use Exemption. Anti-doping laboratories have identified a urinary breakdown product that remained detectable up to a month after a depot dose.
How is triptorelin different from leuprolide?
Both are GnRH agonists that work by the same desensitization mechanism. Triptorelin uses a D-tryptophan substitution at position 6 while leuprolide uses D-leucine. Clinical efficacy is broadly comparable. In the largest head-to-head trial (284 men, monthly dosing), triptorelin actually reached castrate testosterone more slowly than leuprolide at day 29 (91.2% vs 99.3%) but was equivalent from day 57 onward, and 9-month survival was higher with triptorelin (97.0% vs 90.5%), a secondary finding. A small meta-analysis of three studies also reported improved urinary symptom scores on triptorelin, though with moderate-to-high risk of bias. Depot formulation availability differs by region.
Can a single dose of triptorelin restart natural testosterone production?
In the bodybuilding community, a single low-dose injection (100mcg) is claimed to 'reset' the HPG axis after anabolic steroid cycles. The theory is that a brief GnRH pulse (rather than continuous exposure) triggers an LH/FSH surge without causing desensitization. However, the published evidence is a single 2010 case report: a 34-year-old man with prolonged low testosterone after using anabolic steroids bought online was given one 100 mcg dose of triptorelin, and his testosterone was back in the normal range within a month. No controlled trial has tested this in men coming off steroid cycles. The bigger practical danger is product confusion: in healthy male volunteers, a single 3.75 mg one-month depot raised testosterone for a few days and then drove it to low levels by week 4. Triptorelin is also banned for male athletes at all times under WADA class S2, and persistent low testosterone after steroid use warrants evaluation by an endocrinologist.
What is the testosterone flare and why does it matter?
During the first 1-2 weeks of triptorelin therapy, testosterone levels temporarily rise before the pituitary desensitizes. In prostate cancer patients, this flare can worsen symptoms (bone pain, urinary obstruction). Anti-androgen co-therapy (e.g., flutamide or bicalutamide) is often given during this window to block the flare's effects.
How is a GnRH agonist like triptorelin different from a GnRH antagonist like degarelix or relugolix?
GnRH agonists (triptorelin, leuprolide, goserelin) initially over-stimulate GnRH receptors and then cause receptor desensitization — producing the characteristic testosterone flare in the first 1–2 weeks before suppression sets in. GnRH antagonists (injectable degarelix, oral relugolix) directly block the GnRH receptor and achieve castrate-level testosterone within days, with no flare. Antagonists may carry a more favorable cardiovascular signal in patients with pre-existing heart disease, though comparative data is still maturing. Selection depends on flare-risk profile, cardiovascular comorbidity, preferred dosing route (depot injection vs. daily oral), and payer access.
Will my testosterone come back after stopping triptorelin?
In most patients, yes — but recovery is gradual and not always complete. How long it takes depends mostly on age and how long treatment lasted. In a US series of 76 men who stopped androgen deprivation therapy (median 15 months on leuprolide, goserelin, triptorelin, or degarelix), the median time for testosterone to climb back above 240 ng/dL was 19 months, and older age and longer treatment made recovery less likely. In the HERO trial, only 3.2% of men stopping a 3-month leuprolide depot after 48 weeks were back above 280 ng/dL at 90 days, versus 54% after the oral antagonist relugolix; triptorelin was not tested there. In premenopausal women treated for endometriosis or IVF, menstrual cycles typically resume within 1–6 months. In central precocious puberty, the Triptodur label expects the drug's effect on pituitary and gonadal function to disappear within six to twelve months of stopping; in a German follow-up of 50 girls treated with depot triptorelin, all had menarche or resumed periods, at a mean age of 12.3 years.
Who Triptorelin Is NOT For
- •Pregnancy — triptorelin can cause fetal harm; pregnancy is a labeled contraindication for Triptodur, and women who could become pregnant should be counseled on the risk and use effective contraception during therapy.
- •Breastfeeding — not recommended.
- •Known hypersensitivity to triptorelin, GnRH, or any GnRH analog (cross-reactivity is possible).
- •Severe spinal cord compression or urinary tract obstruction in advanced prostate cancer — the testosterone flare can acutely worsen these conditions. The US label advises close monitoring of men with vertebral metastases or urinary obstruction during the first weeks; anti-androgen cover is commonly used, and a GnRH antagonist avoids the flare entirely.
- •Pre-existing severe osteoporosis without bone-protective co-therapy — relative contraindication for extended ADT; bone protection should accompany extended GnRH agonist therapy in at-risk patients.
- •Significant pre-existing cardiovascular disease — not a labeled contraindication, but the label reports increased heart attack, sudden cardiac death, and stroke risk with GnRH agonists in men; a 2023 meta-analysis found fewer cardiovascular events with GnRH antagonists mainly in men with existing heart disease, although the PRONOUNCE trial found no difference.
- •Known or suspected pituitary adenoma — rare pituitary apoplexy has been reported after GnRH agonists, mostly in people with a pituitary adenoma and usually within 2 weeks of the first dose.
- •History of seizures, epilepsy, brain tumors, or cerebrovascular disorders — convulsions have been reported with GnRH agonists including triptorelin; use with caution.
- •Undiagnosed abnormal vaginal bleeding — should be evaluated before initiating gynecologic-indication therapy.
- •Congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, or QT-prolonging medicines — not an absolute contraindication, but the US label says androgen deprivation with triptorelin may prolong the QT interval and advises weighing benefits against risks, correcting electrolytes, and considering periodic ECG and electrolyte monitoring.
- •Pediatric use outside central precocious puberty (Triptodur indication) — not established for other pediatric indications.
Drug & Supplement Interactions
Triptorelin's drug-interaction profile largely mirrors leuprolide's. The US label says triptorelin's metabolism in humans is unknown but unlikely to involve cytochrome P-450 enzymes, and no drug-drug interaction studies have been done, so classical pharmacokinetic interactions are expected to be minimal. The clinically important interactions are pharmacodynamic. Anti-androgens (bicalutamide, flutamide, nilutamide, enzalutamide): co-administration is standard practice during the testosterone flare period and as continued combined androgen blockade. The EMBARK trial, which paired enzalutamide with leuprolide rather than triptorelin, defined a combined approach in high-risk biochemically recurrent disease; triptorelin-specific combination data are limited. QT-prolonging medications: triptorelin can prolong QT interval, and combination with other QT-prolonging agents warrants ECG monitoring and electrolyte management. Diabetic medications: long-term ADT alters insulin sensitivity and increases diabetes risk; medication adjustments may be needed. Antihypertensives and cardiac medications: ADT affects lipid profiles and cardiovascular physiology over time; medication adjustments may be needed. Warfarin: no interaction studies exist; routine INR monitoring should simply continue. Corticosteroids: commonly used together in prostate cancer for symptom management; the combination is intended. Drugs that raise prolactin (some antipsychotics, metoclopramide): both US labels say that, as a precaution, hyperprolactinemic drugs should not be used with triptorelin, because high prolactin reduces the number of pituitary GnRH receptors. Seizure-threshold-lowering drugs (bupropion, SSRIs) deserve caution, since convulsions have been reported in patients taking them. As with any chronic specialty therapy, patients should disclose all prescription, OTC, and supplement use to their prescriber.
Safety Profile
Common Side Effects
Cautions
- • Initial testosterone flare can worsen prostate cancer symptoms — anti-androgen cover often needed
- • Long-term use causes bone mineral density loss
- • Increased risk of heart attack, sudden cardiac death, and stroke has been reported in men on GnRH agonists; the US label calls the risk low but says to weigh it against existing cardiovascular risk factors
- • Metabolic changes including increased risk of diabetes and hyperlipidemia
- • Not for use in pregnancy — can cause fetal harm
- • Using a long-acting depot for a 'restart' suppresses rather than stimulates testosterone: in healthy men a single 3.75 mg depot raised testosterone for a few days, then drove it to low levels by week 4
- • Serious allergic reactions, including anaphylactic shock and angioedema, have been reported
- • Convulsions have been reported, including in people with no seizure history and in people taking seizure-threshold-lowering drugs such as bupropion or SSRIs
- • Severe skin reactions (Stevens-Johnson syndrome/toxic epidermal necrolysis, DRESS, AGEP) were added to the US label in 2025
- • Rare pituitary apoplexy — sudden headache, vomiting, vision changes — has occurred, mostly in people with a pituitary adenoma and usually within 2 weeks of the first dose
- • Pseudotumor cerebri (raised pressure inside the skull) has been reported in children on GnRH agonists, including triptorelin
- • Kidney or liver impairment raises drug exposure 2- to 4-fold
What We Don't Know
Well-characterized safety profile with nearly 40 years of clinical use (first registered in France in 1986) across multiple indications. Long-term cardiovascular and metabolic effects are actively monitored. The off-label single-dose PCT use has no formal safety data.
Legal Status
United States
Triptorelin is FDA-approved as Trelstar (3.75 mg approved June 2000, 11.25 mg June 2001, 22.5 mg March 2010) for advanced prostate cancer and as Triptodur (June 2017) for central precocious puberty in pediatric patients age 2 and older. It is a prescription-only specialty medication, not a controlled substance. Both US labels require administration by, or under the supervision of, a healthcare provider. It is not approved in the US for endometriosis, uterine fibroids, IVF protocols, breast cancer ovarian suppression, or 'post-cycle therapy' use — though these are common indications internationally or in off-label US practice.
International
Approved across major markets globally as Decapeptyl, Diphereline, Gonapeptyl, Pamorelin, and other brand names. International approvals include advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty, female infertility (IVF), reduction of sex drive in adult men with severe sexual deviations (Salvacyl in the UK, initiated and supervised by a psychiatrist), and adjuvant ovarian suppression in breast cancer (premenopausal women receiving tamoxifen or aromatase inhibitor therapy in selected high-risk situations).
Sports & Competition
Triptorelin is prohibited for male athletes at all times, in and out of competition, under WADA Prohibited List class S2.2.1, 'Testosterone-stimulating peptides in males', which covers GnRH and its agonist analogues and names triptorelin; the wording is the same in the 2026 and 2027 Lists, and all S2 substances are non-Specified. It is not an S4 (hormone and metabolic modulator) substance. A man with a genuine medical need, such as prostate cancer, can apply for a Therapeutic Use Exemption. Therapeutic use for prostate cancer or other approved indications under appropriate Therapeutic Use Exemption is permitted; non-therapeutic use is prohibited in and out of competition. Anti-doping laboratories have characterized a urinary metabolite, triptorelin (5-10), that remained detectable up to one month after administration.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Testosterone bounces back within a few weeks of the last triptorelin shot.
Reality
Depot triptorelin is built to keep working for 1, 3, or 6 months, and recovery only begins after it wears off. In a US series of 76 men who stopped androgen deprivation therapy after a median 15 months on several GnRH drugs including triptorelin, the median time to get back to at least 240 ng/dL was 19 months, and older age and longer treatment made recovery less likely. The Triptodur label likewise expects pituitary and gonadal effects to disappear within six to twelve months after stopping.
Myth
Triptorelin and leuprolide work differently — one is an agonist and the other is an antagonist.
Reality
Both are GnRH agonists with the same desensitization mechanism. They differ in amino acid substitution (D-tryptophan at position 6 for triptorelin, D-leucine at position 6 for leuprolide) and in formulation availability (US triptorelin products are intramuscular, while leuprolide comes as intramuscular depots and as Eligard, a subcutaneous polymer injection), but the mechanism is identical and castration efficacy is similar. A systematic review of 16 head-to-head trials found no major differences in testosterone or PSA lowering, while noting the evidence is too thin to call the agents formally equivalent. The GnRH antagonists — degarelix injectable and relugolix oral — are a different class.
Myth
A single low-dose triptorelin injection can safely 'restart' testosterone after anabolic steroid use.
Reality
This bodybuilding-forum claim has no controlled clinical trial support. The pharmacological logic — that a brief GnRH pulse triggers an LH/FSH surge without causing desensitization — is not validated in human trial data, and the claim rests on a single 2010 case report of one man whose testosterone normalized within a month of a 100 mcg dose. A short-acting dose triggers an LH surge that peaks within hours, but a long-acting depot does the opposite: a single 3.75 mg one-month depot drove testosterone to low levels by week 4 in healthy men. Without trials, no one knows how often the approach helps, fails, or delays a proper diagnosis.
Myth
Triptorelin causes permanent infertility.
Reality
GnRH agonist effects are reversible in the majority of patients. Testosterone or estrogen recovery and fertility restoration occur after discontinuation, though recovery can be slow — a median of 19 months in one series of men after a median 15 months of ADT — and is incomplete in some older men after extended ADT. In the PROMISE-GIM6 trial, women given triptorelin during breast cancer chemotherapy were more likely to resume periods than those on chemotherapy alone (72.6% vs 64.0% at 5 years). In a German long-term follow-up of 50 girls treated with depot triptorelin for precocious puberty, all had menarche or resumed periods, and no negative effect on bone density or reproductive function was seen.
Myth
The testosterone flare from triptorelin is a sign the drug isn't working.
Reality
The flare is the expected pharmacology — initial GnRH receptor stimulation produces transient LH/FSH and gonadal hormone elevation before desensitization develops over 2–4 weeks. The flare is exactly why anti-androgen pre-loading is standard practice in advanced prostate cancer with high tumor burden. After the desensitization phase, sustained suppression is the goal and the flare resolves.
Myth
Triptorelin is safer than leuprolide because it has fewer side effects.
Reality
Both agents share essentially identical class-level side effects: hot flashes, fatigue, mood changes, decreased libido, erectile dysfunction, bone-density loss, cardiovascular risk, and metabolic effects. Marketing or anecdotal claims of side-effect differences are not supported by adequately powered comparative data. Selection between the two is typically driven by formulation availability, depot interval preference, payer access, and clinician familiarity rather than meaningful safety differences.
Published Research
30 studiesEfficacy of 24-weekly vs 12-weekly decapeptyl SR treatment in central precocious puberty: a UK multicentre retrospective cohort study.
Treatment of aggressive prostate cancer with triptorelin in real life in France: the TALISMAN study
Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial
GETUG 14 — phase 3 RCT establishing that 4 months of triptorelin + flutamide added to high-dose radiotherapy improved 5-year disease-free survival (84% vs 76%, hazard ratio 0.64) and reduced biochemical failure versus radiotherapy alone in intermediate- and high-risk localized prostate cancer, with no overall survival difference.
PRIORITI: Phase 4 study of triptorelin or active surveillance in high-risk prostate cancer
Phase 4 randomized trial (226 men, China and Russia) of adjuvant triptorelin 11.25 mg for 9 months versus active surveillance after radical prostatectomy in high-risk, node-negative disease. Biochemical relapse-free survival favored triptorelin, but the difference was not statistically significant.
Triptorelin therapy for lower urinary tract symptoms (LUTS) in prostate cancer patients: A systematic meta-analysis
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study
Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis
Assessment of Two Formulations of Triptorelin in Chinese Patients with Endometriosis: A Phase 3, Randomized Controlled Trial
Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
Decreased testosterone recovery after androgen deprivation therapy for prostate cancer
Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review
Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.
Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
The combined TEXT and SOFT analysis in premenopausal hormone receptor-positive breast cancer, with ovarian suppression mostly by triptorelin: exemestane plus ovarian suppression raised 5-year disease-free survival to 91.1%, versus 87.3% with tamoxifen plus ovarian suppression.
Triptorelin for the treatment of endometriosis
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
PROMISE-GIM6: in premenopausal women with early breast cancer, adding triptorelin during chemotherapy cut chemotherapy-induced early menopause from 25.9% to 8.9%; longer follow-up later found no statistically significant difference in pregnancies.
Anabolic steroids purchased on the Internet as a cause of prolonged hypogonadotropic hypogonadism.
The single published case behind the bodybuilding 'restart' idea: a 34-year-old man with prolonged low testosterone after using internet-bought anabolic steroids received one 100 mcg dose of triptorelin, and his testosterone was in the normal range within a month.
A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis
Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
The largest head-to-head trial of the two agonists (284 men, monthly depots). Triptorelin reached castrate testosterone more slowly than leuprolide at day 29 (91.2% vs 99.3%) but maintained castration as effectively thereafter, and 9-month survival was higher with triptorelin (97.0% vs 90.5%).
Comparison of leuprolide acetate and triptorelin in assisted reproductive technology cycles: a prospective, randomized study
Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function.
Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone.
Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH).
Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6.
Quick Facts
- Class
- GnRH Agonist
- Tier
- B
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Sep 2026
- Citations
- 30PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.